Partnerships with Corporations

A $15 Million Strategic Equity Partnership

Celgene Corporation has made a substantial strategic equity investment in Acetylon, receiving a Board observation right however without license or option rights to Acetylon products. Acetylon is currently investigating the combination of Celgene's class-leading myeloma drug, Revlimid® (lenalidomide) with Acetylon's selective HDAC6 inhibitor drug candidate, ACY-1215, in a Phase 1b clinical trial.

Please read the press release for more details.